# A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer

> **NCT04619537** · PHASE2 · UNKNOWN · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 42 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride plus Docetaxel

## Key facts

- **NCT ID:** NCT04619537
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-08
- **Primary completion:** 2021-10
- **Final completion:** 2022-10
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2020-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04619537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04619537, "A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04619537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*